Kevin has more than 16 years’ experience in various illicit finance roles, covering operational and strategy delivery, including managing HMRC’s largest financial investigation team which delivered multi-million pound confiscations, cash forfeitures and established HMRC’s Offender Management and Enforcement Team, ensuring robust oversight of high-harm offenders.
Kevin’s current role is overseeing HMRC’s response to priority IF threats, such as tech-enabled and trade-based money laundering. Kevin is also a FATF assessor, having worked on the Mutual Evaluation Review of the United Arab Emirates. In 2020, alongside The Egmont Group of Financial Intelligence Units and The Netherlands, Kevin also produced an updated FATF report on trends within trade-based money laundering.
In 2022, Kevin received the Keith Hughes Award for Outstanding Contribution to Excellence and Innovation in Financial Investigation. And in 2025, a Merit Certificate from the World Customs Organisation in recognition of his work on a range of international initiatives relating to financial crime.
We hope you enjoyed reading this article
If you would like unlimited access to AML Intelligence premium articles, newsletter delivered twice a week, access to our Global Bank Fines and Penalties database, free access to Boardroom Series events and much more, select one of our subscription options and become a subscriber!
Pharmaceutical Manufacturer Assertio Therapeutics Inc. Agrees to Pay $3.6M to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl Product
US Department of Justice
The Justice Department announced today that Assertio Therapeutics Inc., formerly known as Depomed Inc., (Assertio), a pharmaceutical company headquartered in Lake Forest, Illinois, has agreed to pay $3.6 million to resolve claims that Assertio violated the False Claims Act (FCA) by causing the submission of false claims for the transmucosal immediate-release fentanyl (TIRF) drug Lazanda for individuals who did not have breakthrough cancer pain.
Bruna Szego addresses the public for AMLA in Dublin
AMLA
At the European Anti-Financial Crime Summit in Dublin, Ms. Bruna Szego, the inaugural Chair of the European Anti-Money Laundering Authority (AMLA), delivered a keynote speech, to an audience of public and private sector stakeholders, highlighting the Authority’s strategic priorities and the urgent need for unified, cross-sector action against financial crime.
Ms. Szego underscored the transformative potential of AMLA, describing it as "a significant step ushering in a new chapter of enhanced cooperation and unified action in our shared mission to counter money laundering and terrorism financing."